Cutaneous Melanoma Systematic Diagnostic Workflows and Integrated Reflectance Confocal Microscopy Assessed with a Retrospective, Comparative Longitudinal (2009-2018) Study.
cancer patient pathways
epidemiology
health services research
melanoma
number needed to excise
skin cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
07 Feb 2022
07 Feb 2022
Historique:
received:
13
12
2021
revised:
05
01
2022
accepted:
04
02
2022
entrez:
15
2
2022
pubmed:
16
2
2022
medline:
16
2
2022
Statut:
epublish
Résumé
The increasing global burden of melanoma demands efficient health services. Accurate early melanoma diagnosis improves prognosis. To assess melanoma prevention strategies and a systematic diagnostic-therapeutical workflow (improved patient access and high-performance technology integration) and estimate cost savings. Retrospective analysis of epidemiological data of an entire province over a 10-year period of all excised lesions suspicious for melanoma (melanoma or benign), registered according to excision location: reference hospital (DP) or other (NDP). A systematic diagnostic-therapeutical workflow, including direct patient access, primary care physician education and high-performance technology (reflectance confocal microscopy (RCM)) integration, was implemented. Impact was assessed with the number of lesions needed to excise (NNE). From 40,832 suspicious lesions excised, 7.5% ( Melanoma prevention strategies combined with systematic diagnostic-therapeutical workflow reduced the ratio of nevi excised to identify each melanoma. Total costs may be reduced by as much as 37%.
Sections du résumé
BACKGROUND
BACKGROUND
The increasing global burden of melanoma demands efficient health services. Accurate early melanoma diagnosis improves prognosis.
OBJECTIVES
OBJECTIVE
To assess melanoma prevention strategies and a systematic diagnostic-therapeutical workflow (improved patient access and high-performance technology integration) and estimate cost savings.
METHODS
METHODS
Retrospective analysis of epidemiological data of an entire province over a 10-year period of all excised lesions suspicious for melanoma (melanoma or benign), registered according to excision location: reference hospital (DP) or other (NDP). A systematic diagnostic-therapeutical workflow, including direct patient access, primary care physician education and high-performance technology (reflectance confocal microscopy (RCM)) integration, was implemented. Impact was assessed with the number of lesions needed to excise (NNE).
RESULTS
RESULTS
From 40,832 suspicious lesions excised, 7.5% (
CONCLUSIONS
CONCLUSIONS
Melanoma prevention strategies combined with systematic diagnostic-therapeutical workflow reduced the ratio of nevi excised to identify each melanoma. Total costs may be reduced by as much as 37%.
Identifiants
pubmed: 35159105
pii: cancers14030838
doi: 10.3390/cancers14030838
pmc: PMC8834176
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
JAMA. 2009 Apr 22;301(16):1702-4
pubmed: 19388140
J Am Acad Dermatol. 2020 May;82(5):1158-1165
pubmed: 31931085
J Eur Acad Dermatol Venereol. 2019 Aug;33(8):1522-1528
pubmed: 30868690
Dermatol Pract Concept. 2017 Apr 30;7(2):1-6
pubmed: 28515985
Acta Derm Venereol. 2011 Sep;91(5):499-503
pubmed: 21874217
Int J Cancer. 2000 Dec 1;88(5):838-42
pubmed: 11072258
J Eur Acad Dermatol Venereol. 2008 Feb;22(2):213-8
pubmed: 18211415
Lancet Oncol. 2002 Mar;3(3):159-65
pubmed: 11902502
G Ital Dermatol Venereol. 2015 Oct;150(5):547-63
pubmed: 26140397
Eur J Cancer. 2016 Aug;63:201-17
pubmed: 27367293
Eur J Surg Oncol. 2018 Nov;44(11):1773-1778
pubmed: 30001892
Eur J Cancer Prev. 2015 Mar;24(2):141-9
pubmed: 25089375
J Eur Acad Dermatol Venereol. 2020 Oct;34(10):2268-2279
pubmed: 31997465
Cochrane Database Syst Rev. 2018 Dec 04;12:CD013190
pubmed: 30521681
J Otolaryngol Head Neck Surg. 2015 Dec 02;44:53
pubmed: 26631308
Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):16-27
pubmed: 26667886
PLoS One. 2017 Sep 25;12(9):e0182349
pubmed: 28945758
Eur J Cancer. 2015 Jun;51(9):1039-49
pubmed: 25131265
J Am Acad Dermatol. 2020 Jan;82(1):110-116
pubmed: 31408683
Am J Dermatopathol. 2013 Feb;35(1):74-7
pubmed: 22722468
Lancet. 2018 Sep 15;392(10151):971-984
pubmed: 30238891
Adv Exp Med Biol. 2008;624:89-103
pubmed: 18348450
J Am Acad Dermatol. 2009 Oct;61(4):599-604
pubmed: 19664848
BMJ. 2005 Sep 3;331(7515):481
pubmed: 16081427
J Invest Dermatol. 2016 Jun;136(6):1161-1171
pubmed: 26902923
N Engl J Med. 2006 Jul 6;355(1):51-65
pubmed: 16822996
J Natl Cancer Inst. 2015 Nov 12;108(1):
pubmed: 26563354
Eur J Dermatol. 2003 Jan-Feb;13(1):76-9
pubmed: 12609788
J Eur Acad Dermatol Venereol. 2016 Mar;30(3):413-9
pubmed: 26446299
Melanoma Res. 2013 Apr;23(2):125-31
pubmed: 23358425
Br J Dermatol. 2012 Aug;167 Suppl 2:43-52
pubmed: 22881587
Oncol Ther. 2020 Dec;8(2):191-196
pubmed: 32930972